La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aethlon Medical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aethlon Medical..

Aethlon Medical (NASDAQ:AEMD) Azioni, Catena delle Opzioni

AETHLON MEDICAL INC

Aethlon Medical

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

Biotech

General

AEMD

Aethlon Medical Announces Independent Data Safety Monitoring Board Overseeing AEMD-2022-06 Trial Recommended Advancing Without Modification

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 45.7% to $0.78 during Thursday's pre-market session. The market value of their outstanding shares is at $32.9 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 22.62% to $1.68. The market value of their outstanding shares is at $49.9 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock rose 21.91% to $0.45. The market value of their outstanding shares is at $29.1 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock moved upwards by 17.97% to $5.12. The market value of their outstanding shares is at $562.1 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock rose 16.94% to $15.41. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 16.47% to $6.08. The market value of their outstanding shares is at $135.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares decreased by 31.0% to $2.03 during Thursday's pre-market session. The company's market cap stands at $467.4 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares fell 26.91% to $2.88. The market value of their outstanding shares is at $10.1 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) stock decreased by 20.37% to $33.0. The company's market cap stands at $3.9 billion. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares declined by 18.79% to $2.94. The market value of their outstanding shares is at $68.0 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock declined by 18.37% to $0.36. The market value of their outstanding shares is at $27.4 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 16.6% to $1.21. The market value of their outstanding shares is at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BMGL

CELZ

CGTX

KLTO

LIMN

MREO

NRIX

PASG

PROK

RARE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) rose sharply in today's pre-market trading following a WSJ report <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46332395/wk-kellogg-stock-pops-50-on-potential-3-billion-acquisition">suggesting Ferrero is nearing a deal to acquire the company.</a>
Family-owned Italian candy company Ferrero is closing in on a deal to acquire cereal maker WK Kellogg for roughly $3 billion, according to a Wall Street Journal report. People familiar with the matter reportedly said a deal could be completed as soon as this week.
WK Kellogg shares jumped 50.2% to $26.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Steakholder Foods Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKH#NASDAQ">STKH</a>) surged 137.6% to $4.16 in pre-market trading.</li>
<li>GIBO Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) climbed 51.4% to $0.0512 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) rose 51.1% to $20.00 in pre-market trading as the company posted better-than-expected second-quarter results.</li>
<li>IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) jumped 51.1% to $0.5550 in pre-market trading after gaining 15% on Wednesday. IGC Pharma has been making significant strides in its field. In June, the company highlighted its fiscal year 2025 with clinical progress and Alzheimer's drug development advances. This included the presentation of a scientific poster titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) gained 43.1% to $1.96 in pre-market trading as the company was granted FDA Orphan Drug designation for KLTO-202 for the treatment of amyotrophic lateral sclerosis. </li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 37.4% to $0.0831 in pre-market trading after gaining 8% on Wednesday.</li>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) gained 29.4% to $0.9000 in pre-market trading. Pop Culture Group, a China-based company focused on developing and hosting hip-hop and other entertainment events, completed a private placement on July 4, 2025.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) gained 15% to $7.01 in pre-market trading after climbing 18% on Wednesday.</li>
<li>ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) gained 13.8% to $4.94 in pre-market trading as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) dipped 36.6% to $1.87 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Creative Medical Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares tumbled 25.3% to $2.93 in pre-market trading. Creative Medical Technology has received a notice of allowance for a U.S. patent titled &#8220;Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.&#8221;</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 21.3% to $32.50 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) dipped 17.2% to $3.00 in pre-market trading after gaining 99% on Wednesday.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 15.1% to $8.74 in pre-market trading after the company reported a fourth-quarter adjusted EPS miss.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 13.2% to $1.26 in pre-market trading.</li>
<li>Delixy Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLXY#NASDAQ">DLXY</a>) declined 11.4% to $4.38 in pre-market trading after gaining 24% on Wednesday.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) declined 11% to $1.79 in pre-market trading after dipping 20% on Wednesday.</li>
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) shares fell 10.5% to $5.89 in pre-market trading after gaining over 56% on Wednesday.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 7.7% to $61.60 in pre-market trading. BitMine Immersion Technologies shares dipped 40% on Wednesday after the company filed for a mixed shelf.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo via Shutterstock

BMNR

CPOP

DLXY

GIBO

NCNA

POET

SCAG

STKH

WOLF

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares moved upwards by 56.4% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $25.3 million. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock moved upwards by 11.03% to $7.95. The market value of their outstanding shares is at $580.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares increased by 10.93% to $0.34. The market value of their outstanding shares is at $7.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 9.35% to $5.73. The market value of their outstanding shares is at $163.3 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock moved upwards by 7.73% to $14.2. The company's market cap stands at $930.8 million. The company's, Q2 earnings came out today. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 6.95% to $1.23. The company's market cap stands at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares fell 37.7% to $1.83 during Wednesday's after-market session. The market value of their outstanding shares is at $449.9 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) shares fell 27.66% to $29.98. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares declined by 27.33% to $2.86. The company's market cap stands at $6.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 9.95% to $3.26. The market value of their outstanding shares is at $34.1 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 7.59% to $1.34. The market value of their outstanding shares is at $2.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 6.73% to $0.55. The company's market cap stands at $90.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTS

PSNL

ZJYL

12 Health Care Stocks Moving In Wednesday's After-Market Session

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth assumes Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) with a Neutral rating and announces Price Target of $1.5.

News

Price Target

Initiation

Analyst Ratings

HC Wainwright & Co. Assumes Aethlon Medical at Neutral, Announces Price Target of $1.5

<h3>Gainers</h3>
<ul>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 46.4% to $5.12 during Friday's regular session. The market value of their outstanding shares is at $250.4 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 43.97% to $11.36. The company's market cap stands at $22.7 million. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares moved upwards by 30.88% to $1.74. The market value of their outstanding shares is at $14.4 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) shares increased by 27.72% to $2.58. The company's market cap stands at $163.3 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock moved upwards by 27.52% to $1.14. The company's market cap stands at $111.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 27.39% to $6.65. The company's market cap stands at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock decreased by 44.1% to $0.54 during Friday's regular session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares fell 39.82% to $9.99. The company's market cap stands at $431.8 million. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) stock declined by 37.32% to $2.2. The company's market cap stands at $121.7 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 34.54% to $1.27. The company's market cap stands at $3.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock decreased by 29.83% to $9.39. The company's market cap stands at $17.7 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 29.08% to $0.33. The company's market cap stands at $7.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHV

ADIL

CTOR

CTXR

EYEN

GCTK

IMAB

LYRA

OTRK

12 Health Care Stocks Moving In Friday's Intraday Session

WIIM

Aethlon Medical shares are trading lower after the company reported a Q4 EPS miss.

<h3>Gainers</h3>
<ul>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares increased by 86.0% to $7.74 during Friday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) stock rose 58.75% to $9.97. The market value of their outstanding shares is at $146.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares moved upwards by 38.07% to $1.2. The company's market cap stands at $2.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 36.0% to $7.1. The market value of their outstanding shares is at $2.9 million. </li>
<li>Actuate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) stock moved upwards by 28.69% to $7.49. The company's market cap stands at $114.1 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares rose 22.17% to $5.4. The company's market cap stands at $163.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares declined by 25.3% to $1.45 during Friday's pre-market session. The company's market cap stands at $3.9 million. The company's, Q4 earnings came out yesterday. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) stock declined by 22.3% to $3.73. The company's market cap stands at $217.4 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock decreased by 22.29% to $0.37. The market value of their outstanding shares is at $7.4 million. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) stock decreased by 15.94% to $2.95. The company's market cap stands at $121.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 15.25% to $0.31. The company's market cap stands at $18.6 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock fell 12.66% to $35.67. The market value of their outstanding shares is at $1.1 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACTU

BBLG

BDMD

ESTA

INMB

NAOV

PSTV

YMAB

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 45.2% to $1.25 during Thursday's after-market session. The market value of their outstanding shares is at $2.2 million. </li>
<li>INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) shares increased by 41.08% to $8.86. The company's market cap stands at $172.3 million. </li>
<li>Actuate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) shares increased by 18.04% to $6.87. The market value of their outstanding shares is at $126.3 million. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) shares increased by 13.32% to $0.84. The market value of their outstanding shares is at $17.8 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock rose 11.12% to $0.99. The company's market cap stands at $69.2 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares moved upwards by 7.83% to $5.63. The company's market cap stands at $4.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 20.1% to $1.55 during Thursday's after-market session. The market value of their outstanding shares is at $3.1 million. As per the news, the Q4 earnings report came out today. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares declined by 17.33% to $0.39. The company's market cap stands at $3.8 million. </li>
<li>Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) shares decreased by 12.83% to $3.06. The market value of their outstanding shares is at $131.8 million. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) stock declined by 10.97% to $13.32. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock fell 9.17% to $0.71. The company's market cap stands at $2.1 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares fell 8.6% to $0.34. The market value of their outstanding shares is at $16.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRMD

LIXT

12 Health Care Stocks Moving In Thursday's After-Market Session

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported quarterly losses of $(3.70) per share which missed the analyst consensus estimate of $(1.07) by 244.83 percent. This is a 306.59 percent decrease over losses of $(0.91) per share from the same period last year.

Earnings

Earnings Misses

Aethlon Medical Q4 EPS $(3.70) Misses $(1.07) Estimate

<h3>Companies Reporting Before The Bell</h3>
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is projected to report quarterly loss at $0.11 per share on revenue of $31.47 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $21.08 million. 
• Lindsay (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNN#NYSE">LNN</a>) is expected to report quarterly earnings at $1.40 per share on revenue of $157.90 million. 
• Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $36.72 billion. 
• McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) is estimated to report quarterly earnings at $0.66 per share on revenue of $1.66 billion. 
• Acuity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) is estimated to report quarterly earnings at $4.49 per share on revenue of $1.16 billion. 
<h3>Companies Reporting After The Bell</h3>
• Origin Agritech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEED#NASDAQ">SEED</a>) is likely to report earnings for its first quarter. 
• Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) is estimated to report earnings for its fourth quarter. 
• Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $10.70 billion. 
• American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) is projected to report quarterly loss at $0.11 per share on revenue of $48.46 million. 
• Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $2.75 per share on revenue of $2.38 billion. 
• Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) is projected to report quarterly earnings at $0.47 per share on revenue of $162.20 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AOUT

CNXC

EPAC

HIVE

OESX

SEED

Earnings Scheduled For June 26, 2025

<h3>Gainers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 19.6% to $0.29 during Wednesday's after-market session. The company's market cap stands at $2.3 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) stock moved upwards by 19.19% to $0.5. The market value of their outstanding shares is at $4.0 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares increased by 14.19% to $1.85. The market value of their outstanding shares is at $2.8 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock rose 13.54% to $0.62. The company's market cap stands at $39.7 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares increased by 8.06% to $6.7. The company's market cap stands at $83.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 7.96% to $0.34. The company's market cap stands at $1.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock declined by 32.5% to $0.52 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock fell 7.81% to $0.65. The market value of their outstanding shares is at $3.1 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock decreased by 7.65% to $1.45. The market value of their outstanding shares is at $3.2 million. </li>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) stock fell 7.5% to $1.11. The company's market cap stands at $11.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock fell 7.12% to $2.35. The company's market cap stands at $3.4 million. </li>
<li>Evaxion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares decreased by 7.02% to $2.41. The company's market cap stands at $15.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

EVAX

RVPH

SXTP

UNCY

XTLB

ZVSA

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) will release its quarterly earnings report on Thursday, 2025-06-26. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Aethlon Medical to report an earnings per share (EPS) of $-0.21.
The announcement from Aethlon Medical is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.07, which was followed by a 5.51% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2025/1750867322_0.png" alt="eps graph" />
<h3>Market Performance of Aethlon Medical's Stock</h3>
Shares of Aethlon Medical were trading at $1.62 as of June 24. Over the last 52-week period, shares are down 65.33%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AEMD/earnings">To track all earnings releases for Aethlon Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Aethlon Medical's Earnings

Second Patient in first cohort enrolled and treated at the Royal North Shore Hospital/University of Sydney
Aethlon Advances Hemopurifier&#xAE; Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies
SAN DIEGO, June 18, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4451389-1&amp;h=3638213646&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Fwww.aethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOjhhMGQxZTQ5ODhlNGJjNDNiOTFiOWI3OGQyNTg0NTkyOjY6YjRmZDo1ZDY5N2I5YTA1MGRiODQyMmUyM2NlODE0ODI1OGExZWQzZGVlYzFiODQ3YjNjMmU4YmZjMzY0ZjE1OGJiZmU0OnA6Rg&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the second patient with the&nbsp;Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier. This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda&#xAE; (pembrolizumab) or Opdivo&#xAE; (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was treated with the Hemopurifier June 11, 2025 by Genesis Care and Royal North Shore Hospital/University of Sydney. Professor Stephen Clarke, Medical Oncologist, is the Principal Investigator for the study and the Hemopurifier session was supervised by Dr. Emma O'Lone.
Ongoing progress has been made in our Australian Oncology trial of the Hemopurifier in participants with solid tumors not responding to anti-PD-1 agents. We have now completed Hemopurifier treatments in 2 participants in the first cohort. Our first participant completed the Hemopurifier treatment at Royal Adelaide Hospital on January 29, 2025. Participant # 2 was treated with the Hemopurifier at Royal North Shore/University of Sydney on June 2, 2025. Both participants completed the 4-hour Hemopurifier treatment without device deficiencies or immediate complications. As of June 10, 2025, both patients have completed the pre-specified 7-day safety follow-up period that will be presented to an independent Data Safety Monitoring Board (DSMB) following the treatment of a third patient in the cohort.
The DSMB will review safety data on this first cohort and provide a recommendation to Aethlon Medical Senior Leadership about advancing to the second treatment cohort where 3 participants will receive 2 Hemopurifier treatments during a one-week period. We would expect data on extracellular removal by the Hemopurifier and effects on anti-tumor T cell activity on participants in the first cohort in approximately three months following enrollment of the third patient.

Aethlon Medical Treats Second Patient In Australian Hemopurifier Trial For Solid Tumors Unresponsive To Anti-PD-1 Therapy At Royal North Shore Hospital/University Of Sydney

<a href="https://register.epo.org/application?number=EP21788894" title="https://register.epo.org/application?number=EP21788894">https://register.epo.org/application?number=EP21788894</a>

Aethlon Medical Has Been Granted European Patent Number EP4136453 Titled "LECTIN FOR USE IN METHODS FOR TREATING A SEQUELA OF CORONAVIRUS INFECTION"

https://www.who.int/news/item/09-06-2025-fourth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-upsurge-of-mpox-2024-temporary-recommendations

GOVX

MRNA

TNXP

VRAX

World Health Organization Says MPOX Remains A Public Health Emergency Of International Concern

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Poster Presentation Reviews the Hemopurifier&#xAE; Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples
SAN DIEGO, June 9, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4444407-1&amp;h=3136272918&amp;u=https%3A%2F%2Furl.avanan.click%2Fv2%2F___https%3A%2Faethlonmedical.com%2F___.YXAzOmFldGhsb246YTpvOmI3YWI2N2Q2OWRiZjI1MjAzMDg1MWYzYTRmNWQ4YjYxOjY6NjNiYTpmNzBkM2E2YjIwNTc2MDI1ZjRlZmJiMWVmMzQ5Mzg2MDJmMjk4M2EwZTcwOGM5NDUyOTJiNTY1NWFlNjFlYzhhOnA6VDpO&amp;a=Aethlon+Medical%2C+Inc.">Aethlon Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel &amp; Spa, Santa Fe, NM, United States, August 10-13,2025.
Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective.
Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. &nbsp;EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation.
Aethlon Medical's Hemopurifier&#xAE; is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose.
The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered &nbsp;from COVID-19 in order to examine whether&nbsp; individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively.

Aethlon Medical Announces Poster Presentation At Keystone Symposium On Long COVID And Other Post-Acute Infection Syndromes; Presentation Reviews Hemopurifier Affinity Resin's Ability To Bind Extracellular Vesicles In Long COVID Samples

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 26.7% to $0.29 during Monday's after-market session. The company's market cap stands at $5.2 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock rose 15.38% to $0.01. </li>
<li>Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) stock moved upwards by 13.5% to $2.69. The company's market cap stands at $97.3 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 8.33% to $0.01. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares increased by 7.33% to $1.61. The company's market cap stands at $7.9 million. </li>
<li>Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) stock moved upwards by 6.29% to $0.73. The market value of their outstanding shares is at $118.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 26.3% to $0.24 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares declined by 14.63% to $2.2. The market value of their outstanding shares is at $5.6 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) shares fell 13.47% to $2.7. The market value of their outstanding shares is at $88.2 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock declined by 10.64% to $0.22. The company's market cap stands at $10.9 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 8.42% to $0.38. The market value of their outstanding shares is at $6.1 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 6.26% to $1.2. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMP

ASBP

BDRX

BIAF

CBUS

EKSO

HCTI

LIPO

MSPR

NMRA

PLRZ

12 Health Care Stocks Moving In Monday's After-Market Session

Press Releases

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

Small Cap

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live stream

Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

Comments

Aethlon Medical

Aethlon Medical (AEMD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO